A pilot randomized, open label study to evaluate the effect of a therapeutic HIV vaccine consisting of PENNVAX®-GP (gag, pol, env) and INO-9012 DNA vaccine delivered via electroporation on reducing HIV viral reservoirs in infected individuals, who initiated therapy during the acute/early phase of infectionLearn More
Can valacylovir attenuate inflammation in ART-treated HIV-infected individuals with herpes simplex virus type 2? Trial resultsLearn More
Assessing feasibility of collecting repeated blood and swab samples for herpesviruses in HIV-infected individuals hospitalized with acute illnessLearn More
Pilot project to implement a step-wise investigation that includes Cerebrospinal Fluid analysis as a standard of care for HIV+ individuals with cognitive symptomsLearn More
An observational study of Kaletra®/Celsentri® combination therapyLearn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.